dc.contributor | Hosp Olhos Araraquara | |
dc.contributor | Universidade Federal de São Paulo (UNIFESP) | |
dc.contributor | Univ Araraquara UNIARA | |
dc.contributor | Universidade Estadual Paulista (Unesp) | |
dc.contributor | Johns Hopkins Univ | |
dc.contributor | Univ Calif Irvine | |
dc.contributor | Univ Complutense | |
dc.date.accessioned | 2014-05-20T13:24:54Z | |
dc.date.available | 2014-05-20T13:24:54Z | |
dc.date.created | 2014-05-20T13:24:54Z | |
dc.date.issued | 2010-08-01 | |
dc.identifier | Expert Opinion on Drug Delivery. London: Informa Healthcare, v. 7, n. 8, p. 955-965, 2010. | |
dc.identifier | 1742-5247 | |
dc.identifier | http://hdl.handle.net/11449/7842 | |
dc.identifier | 10.1517/17425247.2010.498817 | |
dc.identifier | WOS:000281032400006 | |
dc.identifier | 9114495952533044 | |
dc.description.abstract | Importance of the field: The use of topical agents poses unique and challenging hurdles for drug delivery. Topical steroids effectively control ocular inflammation, but are associated with the well-recognized dilemma of patient compliance. Although administration of topical antimicrobials as prophylaxis is acceptable among ophthalmologists, this common practice has no sound evidence base Developing a new antimicrobial agent or delivery strategy with enhanced penetration by considering the anatomical and physiological constraints exerted by the barriers of the eye is not a commonly perceived strategy. Exploiting the permeability of the sclera, subconjunctival routes may offer a promising alternative for enhanced drug delivery and tissue targeting.Area covered in this review: Ocular drug delivery strategies were reviewed for ocular inflammation and infections clinically adopted for newer class of antimicrobials, which use a multipronged approach to limit risks of endophthalmitis.What the reader will gain: The analysis substantiates a new transscleral drug delivery therapeutic approach for cataract surgery.Take home message: A new anti-inflammatory and anti-infective paradigm that frees the patient from the nuisance of topical therapeutics is introduced, opening a large investigative avenue for future improved therapies. | |
dc.language | eng | |
dc.publisher | Informa Healthcare | |
dc.relation | Expert Opinion on Drug Delivery | |
dc.relation | 5.553 | |
dc.relation | 1,432 | |
dc.rights | Acesso restrito | |
dc.source | Web of Science | |
dc.subject | antibiotics | |
dc.subject | antimicrobials | |
dc.subject | cataract surgery | |
dc.subject | endophthalimitis | |
dc.subject | eye drops | |
dc.subject | eye infections | |
dc.subject | intraocular penetration | |
dc.subject | ocular drug delivery | |
dc.title | Controlled transscleral drug delivery formulations to the eye: establishing new concepts and paradigms in ocular anti-inflammatory therapeutics and antibacterial prophylaxis | |
dc.type | Artículos de revistas | |